Futura Medical PLC, a consumer healthcare company specializing in innovative sexual health products, held its Annual General Meeting. The company reported that its FY24 is progressing well, with successful full launches in at least ten countries, including key European markets like France, Italy, and Spain. Revenues are in line with market expectations for FY2024, and further launches are expected in the second half of the year in Europe and the Rest of the World. The company plans to provide updated guidance on trading FY24 at the time of its Interim results in September.
Futura is working closely with global consumer healthcare company Haleon to prepare for the US launch of Eroxon, which is advancing well. Haleon plans to launch Eroxon in the US within the next 12 months. The company expressed confidence in the size of its target market and the initial feedback received in the markets where Eroxon has been launched, aiming to make it available to more people globally and move towards profitability in the next 12 months.
Futura Medical PLC is the developer of innovative sexual health products, including Eroxon, a clinically proven product for the treatment of Erectile Dysfunction (ED). Eroxon is a highly differentiated topical gel treatment for ED, available over the counter, and helps men achieve an erection in ten minutes. ED affects 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.